Gland Pharma and Neuland Laboratories have announced a long-term strategic CDMO partnership to establish manufacturing capabilities for sterile Active Pharmaceutical Ingredients (APIs) used in microparticle depot products. According to reports from Business Standard, this collaboration combines Neuland's complex API development and manufacturing expertise with Gland Pharma's global sterile manufacturing capabilities to serve growing worldwide demand for sterile APIs and other complex sterile products. Mr. Saharsh Davuluri, CEO & MD of Neuland Laboratories Limited, emphasized the partnership's strategic value, stating "We believe this partnership creates a strong foundation for sustainable growth and long-term value creation for our customers and both organizations." The agreement was officially announced on August 5, 2026, marking the formal launch of this strategic alliance.
Under the partnership, Gland Pharma will establish a dedicated sterile manufacturing suite at its JNPC facility at Visakhapatnam to support Neuland's growing demand for sterile APIs. As reported by Business Standard, the facility will be constructed and operated to cGMP, USFDA and EU standards, backed by Gland Pharma's proven aseptic manufacturing expertise. The new suite is designed to add approximately 1,400 kg of annual capacity, providing manufacturing flexibility across multiple sterile products while supporting future growth. Mr. Srinivas Sadu, Executive Chairman of Gland Pharma Limited, highlighted the investment's impact, stating "This investment expands our capabilities in sterile API manufacturing and supports increasing customer demand. By leveraging the complementary strengths of both organizations, we will provide a robust and scalable CDMO solution backed by world-class quality, compliance and manufacturing excellence." The addition of approximately 1,400 kg of annual capacity represents a targeted expansion rather than a broad infrastructure overhaul, focusing specifically on microparticle depot products and complex sterile APIs.
The collaboration will offer an integrated CDMO solution encompassing development, scale-up, regulatory support and commercial manufacturing of sterile APIs. According to Business Standard, this integrated approach combines Neuland's deep expertise in complex chemistry, process development, and custom manufacturing with strong track record of serving global innovator and generic pharmaceutical companies, with Gland Pharma's global sterile manufacturing expertise and regulatory compliance track record. The partnership specifically targets high-value microparticle depot products, combining Neuland's expertise in complex chemistry with Gland Pharma's established sterile manufacturing infrastructure to strengthen supply resilience for both innovator and generic pharmaceutical companies seeking reliable sources for complex injectable therapies. Mr. Davuluri further explained that "Together, we are strengthening our ability to deliver the quality, reliability, and supply assurance that innovators and generic companies expect from their CDMO partners."
Gland Pharma has announced a five-year manufacturing and supply agreement with a leading global pharmaceutical company for technology transfer and development of 55 sterile injectable products. As reported by Business Standard, the agreement covers the manufacturing and supply of oncology and non-oncology products across multiple injectable formats, including products in vial, lyophilized vial, ampoule and pre-filled syringe formats, covering both conventional and complex injectables. The agreement spans three manufacturing sites and is expected to generate annualized revenue of $90100 million, with revenue contribution expected to commence from CY29. Mr. Srinivas Sadu, Executive Chairman of Gland Pharma Limited, stated "We are pleased to enter into this strategic collaboration. The partnership highlights the confidence global pharmaceutical companies place in Gland Pharma's development, technology transfer, manufacturing, and supply capabilities. The agreement provides meaningful long-term revenue visibility, supports expansion of our CDMO business, and creates a strong foundation for future growth." The company also has scope to add more products and undertake technology-transfer activities under the partnership, which could increase the eventual revenue opportunity.
This partnership represents a strategic shift toward high-value, technically difficult formulations rather than competing on volume alone in standard sterile injectables. As reported by Business Standard, the collaboration signals a targeted expansion in segments where supply resilience and regulatory compliance are critical differentiators. The partnership leverages the complementary strengths of both entities, with Neuland contributing its deep expertise in complex API development, process development, and custom manufacturing, supported by a strong track record of serving global clients, while Gland Pharma provides its global sterile manufacturing expertise and proven aseptic manufacturing capabilities. Mr. Davuluri noted that "Demand for sterile APIs continues to grow as pharmaceutical companies advance increasingly complex injectable therapies," highlighting how the partnership creates a differentiated platform for global customers that strengthens their ability to deliver the quality, reliability, and supply assurance expected from CDMO partners. The collaboration expands the existing relationship between the Hyderabad-based companies and aims to create a dedicated manufacturing platform for global pharmaceutical innovators and generic drugmakers.
